Thrombocytopenia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major thrombocytopenia markets reached a value of US$ 3.2 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 5.2 Billion by 2034, exhibiting a growth rate (CAGR) of 4.5% during 2024-2034.
The thrombocytopenia market has been comprehensively analyzed in IMARC's new report titled "Thrombocytopenia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Thrombocytopenia refers to a health condition characterized by a low platelet count in the blood. Platelets are tiny blood cells that help with blood clotting to prevent excessive bleeding. When the platelet count drops below normal levels, it can lead to abnormal bleeding or bruising, as well as other life-threatening complications. The symptoms of thrombocytopenia can vary depending on the severity of the disease and the underlying cause. In some cases, individuals suffering from this ailment may experience blood in the stool, urine, and vomit; heavy menstrual periods; tiny red or purple dots on the lower legs; nosebleeds; purpura in the forearms; bleeding gums; malaise; fatigue; bruises; rectal bleeding, etc. The diagnosis of the illness is based on the identification of the patient's indications and complete medical history. Various laboratory tests to confirm a diagnosis include a total blood count, kidney function, liver enzymes, vitamin B12 levels, folic acid levels, peripheral blood smear, erythrocyte sedimentation rate, etc. The healthcare provider may also perform a bone marrow biopsy to evaluate the production of platelets.
The escalating utilization of antineoplastic agents, which cause direct myelosuppression, resulting in decreased production or increased destruction of platelets in the body, is primarily driving the thrombocytopenia market. Besides this, the growing prevalence of numerous associated risk factors, such as autoimmune diseases, hemolytic uremic syndrome, pregnancy, bacterial infections, etc., leading to faster breakdown and a shortage of platelets, is also augmenting the market growth. Furthermore, the widespread adoption of corticosteroids, which effectively work by suppressing the immune system, thereby decreasing the antibodies against platelets, and preventing bleeding, is creating a positive outlook for the market. Apart from this, the inflating demand for therapeutic plasma exchange (TPE) as a treatment option for patients with symptomatic and severe thrombocytopenia who fail to respond to traditional regimens is acting as another significant growth-inducing factor. Moreover, the emerging popularity of thrombopoietin receptor agonists, such as avatrombopag, for treating the condition since they increase platelet production by stimulating the formation and maturation of bone marrow cells is expected to drive the thrombocytopenia market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the thrombocytopenia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for thrombocytopenia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the thrombocytopenia market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the thrombocytopenia market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the thrombocytopenia market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current thrombocytopenia marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the thrombocytopenia market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the thrombocytopenia market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the thrombocytopenia market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (?2018-2034?) of thrombocytopenia across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of thrombocytopenia by age across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of thrombocytopenia by gender across the seven major markets?
How many patients are diagnosed (?2018-2034?) with thrombocytopenia across the seven major markets?
What is the size of the thrombocytopenia patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of thrombocytopenia?
What will be the growth rate of patients across the seven major markets?
Thrombocytopenia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for thrombocytopenia drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the thrombocytopenia market?
What are the key regulatory events related to the thrombocytopenia market?
What is the structure of clinical trial landscape by status related to the thrombocytopenia market?
What is the structure of clinical trial landscape by phase related to the thrombocytopenia market?
What is the structure of clinical trial landscape by route of administration related to the thrombocytopenia market?
The thrombocytopenia market has been comprehensively analyzed in IMARC's new report titled "Thrombocytopenia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Thrombocytopenia refers to a health condition characterized by a low platelet count in the blood. Platelets are tiny blood cells that help with blood clotting to prevent excessive bleeding. When the platelet count drops below normal levels, it can lead to abnormal bleeding or bruising, as well as other life-threatening complications. The symptoms of thrombocytopenia can vary depending on the severity of the disease and the underlying cause. In some cases, individuals suffering from this ailment may experience blood in the stool, urine, and vomit; heavy menstrual periods; tiny red or purple dots on the lower legs; nosebleeds; purpura in the forearms; bleeding gums; malaise; fatigue; bruises; rectal bleeding, etc. The diagnosis of the illness is based on the identification of the patient's indications and complete medical history. Various laboratory tests to confirm a diagnosis include a total blood count, kidney function, liver enzymes, vitamin B12 levels, folic acid levels, peripheral blood smear, erythrocyte sedimentation rate, etc. The healthcare provider may also perform a bone marrow biopsy to evaluate the production of platelets.
The escalating utilization of antineoplastic agents, which cause direct myelosuppression, resulting in decreased production or increased destruction of platelets in the body, is primarily driving the thrombocytopenia market. Besides this, the growing prevalence of numerous associated risk factors, such as autoimmune diseases, hemolytic uremic syndrome, pregnancy, bacterial infections, etc., leading to faster breakdown and a shortage of platelets, is also augmenting the market growth. Furthermore, the widespread adoption of corticosteroids, which effectively work by suppressing the immune system, thereby decreasing the antibodies against platelets, and preventing bleeding, is creating a positive outlook for the market. Apart from this, the inflating demand for therapeutic plasma exchange (TPE) as a treatment option for patients with symptomatic and severe thrombocytopenia who fail to respond to traditional regimens is acting as another significant growth-inducing factor. Moreover, the emerging popularity of thrombopoietin receptor agonists, such as avatrombopag, for treating the condition since they increase platelet production by stimulating the formation and maturation of bone marrow cells is expected to drive the thrombocytopenia market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the thrombocytopenia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for thrombocytopenia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the thrombocytopenia market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the thrombocytopenia market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the thrombocytopenia market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current thrombocytopenia marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the thrombocytopenia market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the thrombocytopenia market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the thrombocytopenia market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (?2018-2034?) of thrombocytopenia across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of thrombocytopenia by age across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of thrombocytopenia by gender across the seven major markets?
How many patients are diagnosed (?2018-2034?) with thrombocytopenia across the seven major markets?
What is the size of the thrombocytopenia patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of thrombocytopenia?
What will be the growth rate of patients across the seven major markets?
Thrombocytopenia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for thrombocytopenia drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the thrombocytopenia market?
What are the key regulatory events related to the thrombocytopenia market?
What is the structure of clinical trial landscape by status related to the thrombocytopenia market?
What is the structure of clinical trial landscape by phase related to the thrombocytopenia market?
What is the structure of clinical trial landscape by route of administration related to the thrombocytopenia market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 THROMBOCYTOPENIA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 THROMBOCYTOPENIA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 THROMBOCYTOPENIA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 THROMBOCYTOPENIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 THROMBOCYTOPENIA - UNMET NEEDS
10 THROMBOCYTOPENIA - KEY ENDPOINTS OF TREATMENT
11 THROMBOCYTOPENIA - MARKETED PRODUCTS
11.1 List of Thrombocytopenia Marketed Drugs Across the Top 7 Markets
11.1.1 Nplate (Romiplostim) - Amgen
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Panzyga (Immune globulin 10%) - Octapharma
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Argatroban - Mitsubishi Chemical
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Tavalisse (Fostamatinib) - Rigel Pharmaceuticals
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Mulpleta (Lusutrombopag) - Shionogi
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 THROMBOCYTOPENIA - PIPELINE DRUGS
12.1 List of Thrombocytopenia Pipeline Drugs Across the Top 7 Markets
12.1.1 VLX 1005 - Veralox Therapeutics
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Rilzabrutinib - Sanofi
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Efgartigimod PH20 SC - argenx
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. THROMBOCYTOPENIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. THROMBOCYTOPENIA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 THROMBOCYTOPENIA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Thrombocytopenia - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Thrombocytopenia - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Thrombocytopenia - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Thrombocytopenia - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Thrombocytopenia - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Thrombocytopenia - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Thrombocytopenia - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Thrombocytopenia - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Thrombocytopenia - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Thrombocytopenia - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Thrombocytopenia - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Thrombocytopenia - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Thrombocytopenia - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Thrombocytopenia - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Thrombocytopenia - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Thrombocytopenia - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Thrombocytopenia - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Thrombocytopenia - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Thrombocytopenia - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Thrombocytopenia - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Thrombocytopenia - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Thrombocytopenia - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Thrombocytopenia - Access and Reimbursement Overview
16 THROMBOCYTOPENIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 THROMBOCYTOPENIA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 THROMBOCYTOPENIA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 THROMBOCYTOPENIA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 THROMBOCYTOPENIA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 THROMBOCYTOPENIA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 THROMBOCYTOPENIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 THROMBOCYTOPENIA - UNMET NEEDS
10 THROMBOCYTOPENIA - KEY ENDPOINTS OF TREATMENT
11 THROMBOCYTOPENIA - MARKETED PRODUCTS
11.1 List of Thrombocytopenia Marketed Drugs Across the Top 7 Markets
11.1.1 Nplate (Romiplostim) - Amgen
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Panzyga (Immune globulin 10%) - Octapharma
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Argatroban - Mitsubishi Chemical
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Tavalisse (Fostamatinib) - Rigel Pharmaceuticals
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Mulpleta (Lusutrombopag) - Shionogi
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 THROMBOCYTOPENIA - PIPELINE DRUGS
12.1 List of Thrombocytopenia Pipeline Drugs Across the Top 7 Markets
12.1.1 VLX 1005 - Veralox Therapeutics
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Rilzabrutinib - Sanofi
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Efgartigimod PH20 SC - argenx
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. THROMBOCYTOPENIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. THROMBOCYTOPENIA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 THROMBOCYTOPENIA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Thrombocytopenia - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Thrombocytopenia - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Thrombocytopenia - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Thrombocytopenia - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Thrombocytopenia - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Thrombocytopenia - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Thrombocytopenia - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Thrombocytopenia - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Thrombocytopenia - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Thrombocytopenia - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Thrombocytopenia - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Thrombocytopenia - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Thrombocytopenia - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Thrombocytopenia - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Thrombocytopenia - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Thrombocytopenia - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Thrombocytopenia - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Thrombocytopenia - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Thrombocytopenia - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Thrombocytopenia - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Thrombocytopenia - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Thrombocytopenia - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Thrombocytopenia - Access and Reimbursement Overview
16 THROMBOCYTOPENIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 THROMBOCYTOPENIA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 THROMBOCYTOPENIA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
